[Federal Register Volume 87, Number 206 (Wednesday, October 26, 2022)]
[Notices]
[Page 64783]
[FR Doc No: 2022-23292]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings

    Take notice that the Commission has received the following Natural
Gas Pipeline Rate and Refund Report filings:

Filings Instituting Proceedings

    Docket Numbers: CP23-5-000.
    Applicants: Northern Indiana Public Service Company, LLC.
    Description: Application of Northern Indiana Public Service Company
LLC for a Limited Jurisdiction Certificate of Public Convenience and
Necessity.
    Filed Date: 10/19/2022.
    Accession Number: 20221019-5122.
    Comment Date: 5 p.m. ET 11/9/22.

    Docket Numbers: RP23-44-000.
    Applicants: Southern LNG Company, L.L.C.
    Description: Sec.  4(d) Rate Filing: SLNG Electric Power Cost
Adjustment--2022 to be effective 12/1/2022.
    Filed Date: 10/19/22.
    Accession Number: 20221019-5048.
    Comment Date: 5 p.m. ET 10/31/22.

    Docket Numbers: RP23-45-000.
    Applicants: Iroquois Gas Transmission System, L.P.
    Description: Sec.  4(d) Rate Filing: 10.20.22 Negotiated Rates--
Twin Eagle Resource Management, LLC R-7300-25 to be effective 11/1/
2022.
    Filed Date: 10/20/22.
    Accession Number: 20221020-5016.
    Comment Date: 5 p.m. ET 11/1/22.

    Docket Numbers: RP23-46-000.
    Applicants: Iroquois Gas Transmission System, L.P.
    Description: Sec.  4(d) Rate Filing: 10.20.22 Negotiated Rates--
Twin Eagle Resource Management LLC R-7300-26 to be effective 11/1/2022.
    Filed Date: 10/20/22.
    Accession Number: 20221020-5017.
    Comment Date: 5 p.m. ET 11/1/22.

    Docket Numbers: RP23-47-000.
    Applicants: Iroquois Gas Transmission System, L.P.
    Description: Sec.  4(d) Rate Filing: 10.20.22 Negotiated Rates--
Shell Energy North America (US), L.P. R-2170-20 to be effective 11/1/
2022.
    Filed Date: 10/20/22.
    Accession Number: 20221020-5020.
    Comment Date: 5 p.m. ET 11/1/22.

    Docket Numbers: RP23-48-000.
    Applicants: Iroquois Gas Transmission System, L.P.
    Description: Sec.  4(d) Rate Filing: 10.20.22 Negotiated Rates--
Shell Energy North America (US), L.P. R-2170-21 to be effective 11/1/
2022.
    Filed Date: 10/20/22.
    Accession Number: 20221020-5023.
    Comment Date: 5 p.m. ET 11/1/22.

    Docket Numbers: RP23-49-000.
    Applicants: Iroquois Gas Transmission System, L.P.
    Description: Sec.  4(d) Rate Filing: 10.20.22 Negotiated Rates--
Mercuria Energy America, LLC R-7540-23 to be effective 11/1/2022.
    Filed Date: 10/20/22.
    Accession Number: 20221020-5026.
    Comment Date: 5 p.m. ET 11/1/22.

    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.

Filings in Existing Proceedings

    Docket Numbers: PR22-65-001.
    Applicants: Midland-Permian Pipeline LLC.
    Description: Sec.  284.123 Rate Filing: Midland-Permian Pipeline
LLC Amended Statement of Operating Conditions to be effective 9/14/
2022.
    Filed Date: 10/19/22.
    Accession Number: 20221019-5117.
    Comment Date: 5 p.m. ET 11/2/22.

    Docket Numbers: RP22-1065-000.
    Applicants: Iroquois Gas Transmission System, L.P.
    Description: Refund Report: 10.20.22 Stipulation and Settlement
Agreement Refund Report to be effective N/A.
    Filed Date: 10/20/22.
    Accession Number: 20221020-5067.
    Comment Date: 5 p.m. ET 11/1/22.

    Any person desiring to protest in any the above proceedings must
file in accordance with Rule 211 of the Commission's Regulations (18
CFR 385.211) on or before 5:00 p.m. Eastern time on the specified
comment date.
    The filings are accessible in the Commission's eLibrary system
(https://elibrary.ferc.gov/idmws/search/fercgensearch.asp) by querying
the docket number.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: October 20, 2022.
Kimberly D. Bose,
Secretary.
[FR Doc. 2022-23292 Filed 10-25-22; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 82, Number 103 (Wednesday, May 31, 2017)]
[Notices]
[Pages 24977-24980]
[FR Doc No: 2017-11188]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0623]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Voluntary Cosmetic Registration Program

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information, and
to allow 60 days for public comment in response to the notice. This
notice invites comments on the collection of information associated
with our Voluntary Cosmetic Registration Program (VCRP).

DATES: Submit either electronic or written comments on the collection
of information by July 31, 2017.

ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before July 31, 2017. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of July 31, 2017. Comments received by
mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov/.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov/
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov/.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2010-N-0623 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Voluntary Cosmetic Registration
Program.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov/ or at the Division of Dockets Management between
9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov/. Submit both copies to the Division of Dockets
Management. If you do not wish your name and contact information to be
made publicly available, you can provide this information on the cover
sheet and not in the body of your comments and you must identify this
information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov/ and insert the docket number, found in brackets in
the

heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Ila Mizrachi, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A63, 11601
Landsdown St., North Bethesda, MD 20852,<PHONE_NUMBER>,
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
    With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Voluntary Cosmetic Registration Program--21 CFR Parts 710 and 720 OMB
Control Number 0910-0027--Extension

    The Federal Food, Drug, and Cosmetic Act (the FD&C Act) provides us
with the authority to regulate cosmetic products in the United States.
Cosmetic products that are adulterated under section 601 of the FD&C
Act (21 U.S.C. 361) or misbranded under section 602 of the FD&C Act (21
U.S.C. 362) may not be distributed in interstate commerce. We have
developed the VCRP to assist us in carrying out our responsibility to
regulate cosmetics.
    FDA is revising forms for the VCRP (Forms FDA 2511, 2512, 2512a,
and 2514) currently approved under OMB control number 0910-0027,
``Voluntary Cosmetic Registration Program,'' for the following reasons:
(1) Modernizing the forms; (2) decreasing burden to filers who complete
the forms; and (3) reducing the time it will take FDA to review each
submission. In addition, Form FDA 2514 will be eliminated as it
duplicates information that is currently located on Form FDA 2512. FDA
requests PRA approval for the proposed changes to these forms, and for
the elimination of Form FDA 2514.
    Participation in the VCRP is voluntary under provisions found in
sections parts 710 and 720 (21 CFR parts 710 and 720). Participants
have the option of submitting information via paper forms or via the
online interface. The term ``form'' refers to both the paper form and
the online system.
    Currently, in part 710, we request that establishments that
manufacture or package cosmetic products voluntarily register with us
using Form FDA 2511 entitled ``Registration of Cosmetic Product
Establishment.'' The term ``Form FDA 2511'' refers to both the paper
and online versions of the form. The online version of Form FDA 2511 is
available on our VCRP Web site at https://www.fda.gov/Cosmetics/RegistrationProgram/default.htm. We strongly encourage online
registration of Form FDA 2511 because it is faster and more efficient
for the filer and the Agency. A registering facility will receive
confirmation of online registration, including a registration number by
email. The online system also allows for amendments to past
submissions.
    Because registration of cosmetic product establishments is not
mandatory, voluntary registration provides FDA with the best
information available about the locations, business trade names, and
types of activity (manufacturing or packaging) of cosmetic product
establishments. We place the registration information in a computer
database and use the information to generate mailing lists for
distributing regulatory information and for inviting firms to
participate in workshops on topics in which they may be interested.
Registration is permanent, although we request that respondents submit
an amended Form FDA 2511 if any of the originally submitted information
changes.
    Currently, under part 720, FDA requests firms that manufacture,
pack, or distribute cosmetics to file with the Agency an ingredient
statement for each of their products. Filing of cosmetic product
ingredient statements is voluntary. Ingredient statements for new
submissions are reported on Form FDA 2512, ``Cosmetic Product
Ingredient Statement,'' and on Form FDA 2512a, a continuation form.
Amendments to product formulations also are reported on Forms FDA 2512
and FDA 2512a. When a firm discontinues the commercial distribution of
a cosmetic, FDA requests that the firm file Form FDA 2514, ``Notice of
Discontinuance of Commercial Distribution of Cosmetic Product
Formulation''; however, filers may also notify FDA that they have
discontinued a cosmetic product formulation by submitting an amended
Form FDA 2512, which would obviate the need for Form FDA 2514. If any
of the information submitted on these forms is confidential, the firm
may submit a request for confidentiality of a cosmetic ingredient.
    FDA's proposed changes to the forms through the use of an
electronic submission system have been designed to make it easier for
participants to provide information to FDA about their products. They
also assist participants, through interactive question and response
scenarios, to identify submissions that will be ineligible to be
accepted in VCRP because they do not meet parts 710 and 720
requirements. The electronic submission system is expected to reduce
burden currently associated with the manual identification process for
filers and FDA. The rejection rate for ineligible submissions when
using the current forms is high: 51 percent for new accounts, 43
percent for Form FDA 2511 registrations, and 7 percent for Form FDA
2512 filings (2010-2016).
    The revised forms include the addition of links between Forms FDA
2511 and 2512, clarification of what information should be entered onto
the forms, additional self-identifying fields, removal of certain
duplicative fields, and the deletion of Form FDA 2514. These changes
are needed because both VCRP voluntary filer participation and FDA
resources required to administer VCRP have increased significantly
since 2014 (i.e., increases in new accounts (156 percent), Form FDA
2511 registrations (405 percent), Form FDA 2512 filings (67 percent),
and FDA review hours (59 percent) in 2016.)
    FDA's current process confirms that each submission meets the
requirements established in parts 710 and 720 through the use of a
manual process for

both filers and FDA reviewers that can result in a long waiting period
where filers must wait and respond to questions generated by FDA, which
may result in a high rejection rate. FDA projects a significant
reduction in rejection rates when using the revised forms. Examples of
possible burden savings for participants and FDA include:
    (1) Form FDA 2511 asks filers if they are a manufacturer or packer;
however, distributors and retailers have checked these boxes in error
when neither applies to them because there are no distributor or
retailer checkboxes on Form FDA 2511. Retailers have also filed Form
FDA 2512 in error even though only manufacturers, packers, and
distributors are permitted to do so. To correct these issues, FDA
revised Form FDA 2511 by updating the field that allows filers to
indicate the ``TYPE OF ESTABLISHMENT: MANUFACTURER/PACKER/OTHER
(Distributor or Retailer)'' and updating the field on Form FDA 2512
allowing the filer to indicate ``WHO IS FILING THIS STATEMENT:
MANUFACTURER/PACKER/DISTRIBUTOR/OTHER (Retailer).''
    (2) FDA revised Form FDA 2511 and added questions asking, ``Are you
the owner or operator of this facility?'' and ``Is the address on this
form the location of a cosmetic manufacturing and/or packing
facility?''
    (3) FDA also revised Form FDA 2512 and added questions asking, ``Is
this product currently commercially distributed (annual sales exceed
$1,000) in the United States?'', ``PRODUCT WEBSITE'', and ``Attach
images of the front and back product labels to this form'' to ensure
that only cosmetics in commercial distribution in the United States are
filed in the VCRP.
    (4) FDA linked Forms FDA 2511 and 2512 to reduce burden to filers
who create multiple copies of Form FDA 2512 that share the same
establishment addresses.
    (5) FDA clarified the information that should be included on the
forms by attaching simplified instructions and a link to VCRP online on
Forms FDA 2511, 2512, and 2512a and adding titles and locations of
various fields throughout Forms FDA 2511, 2512, and 2512a. We also
added self-identifying fields such as phone number, email, and
alternative authorized individual to Form FDA 2511 and 2512 to
facilitate communication with the filers.
    (6) We also removed fields that have no modern use or request
redundant information in multiple locations.
    (7) We removed Form FDA 2514 in its entirety due to redundancy. (As
noted, filers may notify FDA that they are discontinuing a cosmetic
product formulation on Form FDA 2512).
    FDA's online filing system is available on FDA's VCRP Web site at
https://www.fda.gov/Cosmetics/RegistrationProgram/default.htm. The
online filing system contains the online versions of Forms FDA 2511,
2512, and 2512a.
    We place cosmetic product filing information in a computer database
and use the information when FDA receives inquiries about cosmetics
marketed in the United States. Because filing of cosmetic product
formulations is not mandatory, voluntary filings with FDA provide us
with the best information available about cosmetic products,
ingredients, frequency of use, businesses engaged in the manufacture
and distribution of cosmetics, and approximate rates of product
discontinuance and formula modifications. The information assists our
scientists in evaluating reports of adverse events submitted via
MedWatch and Field Operators (FACTS). We also use the information in
identifying future research projects, to evaluate the levels and safety
of certain ingredients in cosmetics.
    Links to explanations of the revisions to Forms FDA 2511, 2512, and
2512a and instructions are available at https://www.fda.gov/Cosmetics/RegistrationProgram/default.htm and entitled ``Voluntary Cosmetic
Registration Program.''
    We estimate the burden of this collection of information as
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                           Number of
        21 CFR Section or Part             Form No.        Number of     responses per   Total annual       Average burden  per response     Total hours
                                                          respondents     respondent       responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Part 710 (registrations).............  FDA 2511 \2\                934               1             934  0.20 (12 minutes)..................          187
720.1 through 720.4 (new submissions)  FDA 2512 \3\              7,108               1           7,108  0.33 (20 minutes)..................        2,346
720.6 (amendments)...................  FDA 2512                  4,049               1           4,049  0.17 (10 minutes)..................          688
720.6 (notices of discontinuance)....  FDA 2512                     95               1              95  0.10 (6 minutes)...................           10
720.8 (requests for confidentiality).  ...............               1               1               1  2..................................            2
                                      ------------------------------------------------------------------------------------------------------------------
    Total............................  ...............  ..............  ..............  ..............  ...................................        3,233
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
\2\ The term ``Form FDA 2511'' refers to both the paper Form FDA 2511 and online Form FDA 2511 in the online system known as the VCRP, which is
  available at https://www.fda.gov/Cosmetics/RegistrationProgram/default.htm.
\3\ The term ``Form FDA 2512'' refers to the paper Forms FDA 2512, and 2512a and online Form FDA 2512 in the online system known as the VCRP, which is
  available at https://www.fda.gov/Cosmetics/RegistrationProgram/default.htm.

    We base our estimate of the total annual responses on paper and
online submissions received during calendar year 2016. We base our
estimate of the hours per response upon information from cosmetic
industry personnel and FDA experience entering data submitted on paper
Forms FDA 2511, 2512, and 2512a into the online system.
    We estimate that, annually, 934 establishments that manufacture or
package cosmetic products will each submit 1 registration on Form FDA
2511, for a total of 934 annual responses. Each submission is estimated
to take 0.20 hour per response for a total of 186.8 hours, rounded to
187. The number of Form FDA 2511 submissions has increased 405 percent
compared to 2014 and we have no indication that this submission rate
will stop increasing. We estimate that, annually, firms that
manufacture, pack, or distribute cosmetics will file 7,108 ingredient
statements for new or amended submissions on Forms FDA 2512 and FDA
2512a. Each submission is estimated to take 0.33 hour per response for
a total of 2345.64 hours, rounded to 2,346. We estimate the number of
Form FDA 2512 submissions to increase 67 percent compared to 2014 and
we have no indication that this submission rate will stop increasing.
We estimate that, annually, firms that manufacture, pack, or distribute
cosmetics will file 4,049 amendments to

product formulations on Forms FDA 2512 and FDA 2512a. Each submission
is estimated to take 0.17 hour per response for a total of 688.33
hours, rounded to 688. We estimate that, annually, firms that
manufacture, pack, or distribute cosmetics will file 95 notices of
discontinuance on Form FDA 2512. Each submission is estimated to take
0.10 hour per response for a total of 9.5 hours, rounded to 10. We
estimate that, annually, one firm will file one request for
confidentiality. Each such request is estimated to take 2 hours to
prepare for a total of 2 hours. Thus, the total estimated hour burden
for this information collection is 3,233 hours.

    Dated: May 25, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-11188 Filed 5-30-17; 8:45 am]
 BILLING CODE 4164-01-P